Clinical trials: Neoplasm, Oral
Castration-resistant Prostate Cancer
Oral Calcitriol With Ketoconazole in CRPC
The aim of this study is to estimate the PSA response rate with the use of ketoconazole (400mg QD + hydrocortisone 20mg AM, 10 mg PM) among men with CRPC in whom disease has progressed despite abiraterone
- Trial name
- NCT03261336
- Testing
- Calcitriol, Ketoconazole, Hydrocortisone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Donald Trump, MD
Cancer, Chronic Myelomonocytic Leukemia
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Study and Dose Rationale The safety profile of clofarabine appears acceptable within the target populations studied to date in the clinical studies summarized in Section 2.3.
- Trial name
- NCT00708721
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Solid Tumors
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select solid tumors.
- Trial name
- NCT01286467
- Testing
- PF-04449913
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Radiation Induced Oral Mucositis
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in…
- Trial name
- NCT02508389
- Testing
- Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Intensity-Modulated Radiation Therapy
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 223 people
- Sponsor
- Galera Therapeutics, Inc.
Advanced Solid Tumors
Phase 1 Trial of Oral Ixabepilone
This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21 days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and safety of this dosing schedule in participants…
- Trial name
- NCT00632424
- Testing
- Ixabepilone (oral formulation)
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- R-Pharm
Pain
Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain
As part of the Pediatric Research Equity Act (PREA) commitment, the objectives of the study are to characterize the pharmacokinetic (PK) profile and to determine the safety and tolerability of diclofenac potassium oral solution…
- Trial name
- NCT02287350
- Testing
- diclofenac potassium oral solution
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Depomed
Head and Neck Cancer
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00423930
- Testing
- bevacizumab, cisplatin, conventional surgery
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
Monotherapy Dose Finding With BI 847325 in Solid Tumours
The aim of the Phase Ia (dose escalation) part of this trial is to assess the maximum tolerated dose (MTD) of BI 847325 administered at escalating doses in 2 treatment arms.
- Trial name
- NCT01324830
- Testing
- day 1 to day 5, day 1 to day 14
- Where
- 2 sites in Belgium
- Volunteers
- 69 people
- Sponsor
- Boehringer Ingelheim
Thrombocytopaenia
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or…
- Trial name
- NCT01147809
- Testing
- Eltrombopag olamine
- Where
- 86 sites in United States, Belgium and 11 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Dysphagia, Oral Pharyngeal Cancer
Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy
Patients with head and neck cancer treated with chemoradiation, often develop a treatment associated dysphagia. The common complaint is foods sticking in the pharynx.
- Trial name
- NCT02564887
- Testing
- Iowa Oral Performance Instrument
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jonas Johnson
Head and Neck Cancer
Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects.
- Trial name
- NCT00820248
- Testing
- panitumumab, cisplatin, 3-dimensional conformal radiation therapy
- Where
- 19 sites in Canada
- Volunteers
- 320 people
- Sponsor
- NCIC Clinical Trials Group
Head and Neck Cancer, Xerostomia
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) and pilocarpine may help to relieve chronic xerostomia (dry mouth).
- Trial name
- NCT00656513
- Testing
- Pilocarpine, ALTENS
- Where
- 20 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Radiation Therapy Oncology Group
Glioblastoma
Bosutinib in Adult Patients With Recurrent Glioblastoma
For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells.
- Trial name
- NCT01331291
- Testing
- bosutinib
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This randomized phase III trial studies chemotherapy to see how well it works with or without bevacizumab in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or that has spread to other…
- Conditions
- Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- NCT00588770
- Testing
- Bevacizumab, Carboplatin, Cisplatin
- Where
- 779 sites in United States, Puerto Rico and 1 more
- Volunteers
- 403 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard therapy.
- Trial name
- NCT02157883
- Testing
- Pharmacokinetic sampling, AZD9291, Itraconazole
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Lung Cancer, Precancerous Condition
Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
RATIONALE: Calcitriol may prevent lung cancer in patients with metaplasia or dysplasia of the lungs. PURPOSE: This clinical trial is studying the side effects and best dose of calcitriol in preventing lung cancer in current…
- Conditions
- Lung Cancer, Precancerous Condition, Tobacco Use Disorder
- Trial name
- NCT00690924
- Testing
- calcitriol, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Tobacco Use Disorder, Oral Nicotine Pouch Use
Switching to Potential Reduced Exposure Products in Adult Smokers
This study aims to assess the feasibility, acceptability, and the potential harm reduction of switching to potentially lower risk, oral nicotine pouches in adult smokers.
- Conditions
- Tobacco Use Disorder, Oral Nicotine Pouch Use, Smoking Behaviors, Harm Reduction
- Trial name
- ZYN (NCT04250727)
- Testing
- ZYN
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Metastatic Castration Resistant Prostate Cancer
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- RAMP (NCT04179396)
- Testing
- Rucaparib, Enzalutamide, Abiraterone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- pharmaand GmbH